Ovarian cancer remains one of the leading causes worldwide of death from cancer in women [1]. One of the major reasons for the poor survival rate of ovarian cancer is that most ovarian cancers are identified at an advanced stage [2], and patients experience disease recurrence at some point in their lives [27]. Aggressive optimal cytoreductive surgery plus postoperative administration of chemotherapy is the currently recommended treatment for advanced stage ovarian cancer [3]. Of note, the achievement of optimal cytoreduction is one of the most important factors influencing prognosis.